ERBB2 and gastroesophageal junction adenocarcinoma: Another ongoing trial (NCT04276493) is testing ZW25 in combination with chemotherapy and the anti-PD-1 antibody tislelizumab as a first-line treatment of patients with HER2-positive metastatic G/GEJ adenocarcinoma.